CTOs on the Move

Hunstman Expandable Polymers Co.

www.hunstman.com

 
Hunstman Expandable Polymers Co. is a High Point, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Cleo

Cleo is the support system for working families. With its integrated family benefits platform, Cleo combines proactive, expert guidance with an intuitive engagement hub to help connect families with the support they need to be their best at home and at work.

Season

Season Health is a food as medicine platform that provides clinical nutrition care, meal recommendations, education, and food delivery to people with chronic conditions such as diabetes and kidney disease.

SignalPET®

SignalPET offers advanced artificial intelligence-supported veterinary radiology. See how SignalPET can make a difference for your practice.

HealthLeaders-InterStudy

HealthLeaders-InterStudy is a Nashville, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

scPharmaceuticals

scPharmaceuticals, based in Lexington, MA, is a privately held biopharmaceutical company developing a portfolio of transformative pharmaceutical products for subcutaneous delivery. Based on widely used generic drugs that currently require intravenous or intramuscular injections, our innovative products will be administered subcutaneously via a proprietary patch pump. This avoids material risks and costs associated with the current delivery options. Our lead products are the first subcutaneous formulations of furosemide (the most widely used parenteral diuretic in treating heart failure) and ceftriaxone (the most widely used parenteral antibiotic outside the hospital setting). Our novel furosemide formulation enables convenient anytime anywhere use, for example in an outpatient setting instead of the emergency room or other in-patient settings. For ceftriaxone and other antibiotics, subcutaneous administration eliminates the need for PICCs (peripherally inserted central catheters), which are associated with serious complications, frequent adverse events and high medical cost. For further information on how we are transforming the administration of parenteral drugs.